DelveInsight, a leading market research and consulting firm, has recently published an in-depth report on the Chemotherapy Induced Peripheral Neuropathy pipeline, providing valuable insights into emerging therapies, companies, and future outlooks.
DelveInsight’s, “Chemotherapy Induced Peripheral Neuropathy Pipeline Insight 2023” report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Chemotherapy Induced Peripheral Neuropathy pipeline landscape. It covers the Chemotherapy Induced Peripheral Neuropathy pipeline drug profiles, including Chemotherapy Induced Peripheral Neuropathy clinical trials and nonclinical stage products. It also covers the Chemotherapy Induced Peripheral Neuropathy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
To explore more information on the latest breakthroughs in the Chemotherapy Induced Peripheral Neuropathy Pipeline treatment landscape of the report, click here @ Chemotherapy Induced Peripheral Neuropathy Pipeline Outlook
Key Takeaways from the Chemotherapy-Induced Peripheral Neuropathy Pipeline Report
For further information, refer to the detailed Chemotherapy Induced Peripheral Neuropathy Unmet Needs, Chemotherapy Induced Peripheral Neuropathy Market Drivers, and Chemotherapy Induced Peripheral Neuropathy Market Barriers, click here for Chemotherapy Induced Peripheral Neuropathy Ongoing Clinical Trial Analysis
Chemotherapy Induced Peripheral Neuropathy Overview
Chemotherapy-induced painful neuropathy (CIPN) is a predominantly sensory neuropathy that may be accompanied by motor and autonomic changes. CIPN is a major dose-limiting side effect of several first-line chemotherapeutic agents. The symptoms of CIPN include tingling, pain, decreased sensation, increased sensitivity to touch, temperature, pressure, pain; muscle weakness, and/or irreversible nerve damage.
Request a sample and discover the recent advances in Chemotherapy Induced Peripheral Neuropathy Ongoing Clinical Trial Analysis and Medications, click here @ Chemotherapy Induced Peripheral Neuropathy Treatment Landscape
Chemotherapy Induced Peripheral Neuropathy Emerging Drugs Profile
MN-166 (ibudilast) is a first-in-class, orally bioavailable, small molecule macrophage migration inhibitory factor inhibitor and phosphodiesterase (PDE) -4 and -10 inhibitor that suppresses pro-inflammatory cytokines and promotes neurotrophic factors. MN-166 (ibudilast)’s anti-neuroinflammatory and neuroprotective actions have been demonstrated in preclinical and clinical studies and the molecule is currently under Phase II development for the treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN) (CIPN).
ART-123, a recombinant human soluble thrombomodulin composed of the extracellular domain of thrombomodulin. The drug is in Phase II clinical studies for the treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN), and solid tumors. In 2008, ART-123 was approved for the treatment of disseminated intravascular coagulation (DIC) in Japan.
Dive deep into rich insights for drugs for Chemotherapy Induced Peripheral Neuropathy Market Drivers and Chemotherapy Induced Peripheral Neuropathy Market Barriers, click here @ Chemotherapy Induced Peripheral Neuropathy Unmet Needs and Analyst Views
Chemotherapy Induced Peripheral Neuropathy Pipeline Therapeutics Assessment
There are approx. 13+ key companies which are developing the therapies for Chemotherapy Induced Peripheral Neuropathy (CIPN). The companies which have their Chemotherapy Induced Peripheral Neuropathy (CIPN) drug candidates in the most advanced stage, i.e. Phase II include, MediciNova.
Scope of the Chemotherapy Induced Peripheral Neuropathy Pipeline Therapeutics Assessment
Got Queries? Find out the related information on Chemotherapy Induced Peripheral Neuropathy Mergers and acquisitions, Chemotherapy Induced Peripheral Neuropathy Licensing Activities @ Chemotherapy Induced Peripheral Neuropathy Emerging Drugs, and Recent Trends
Table of Content
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/consulting-services